NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Company watch  «  1  2  3  4  5  » 
found files: 574
GlaxoSmithKline »03/08/2007 [Company watch]
Sinovac Enters Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Lt

Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in China, today announced it has entered into an Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd. (or GSK China). GSK China and Sinovac will market and promote Anflu(R), a seasonal influenza vaccine developed and manufactured by Sinovac....   more»

Wuxi Pharma Tech »25/07/2007 [Company watch]
Wuxi Pharma TechPlans $120Million US public offering

WuXi PharmaTech, the biggest Chinese contract research organisation (CRO), has put an end to weeks of speculation by officially announcing it plans an initial public offering (IPO) on the New York Stock Exchange....   more»

Sundia MediTech Company,Ltd.
»12/07/2007 [Company watch]
CRO Company Sundia Named One of China\\\'s Top 50 to Invest In

Today, Sundia MediTech (Shanghai) Company was named one of the 50 best companies for investment in China by the top venture capital investors. Sundia ranked #16 of Venture 50, an event organized by Zero2IPO, an advisory firm for China investment....   more»

Novartis »07/08/2007 [Company watch]
Novartis delivers strong performance in first half of 2007 (H1 - Report)

...   more»

Bridge (Vital Bridge) »08/08/2007 [Company watch]
Bridge Pharma\\\\\\\'s China facility receives AAALAC accreditation

US-based Bridge Pharmaceuticals’ facility in China has been awarded full accreditation by the Council on Accreditation of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International).Bridges facility in Beijing (Vital Bridge China) is one of only seven toxicology facilities in China to receive this recognition, and Bridge claims that it is the first US-based company to offer toxicology services in multispecies at both locations in the US and China....   more»

Wuxi Pharma Tech »10/08/2007 [Company watch]
Wuxi Raises $185Million from IPO

The NYSE listing of the Chinese drug research company receives substantial demand, enabling it to price 8% higher than the top of the range....   more»

VENTURE PHARM SERVICE--VPScro »27/07/2007 [Company watch]
Raising HK$ 97 million-- VPS-CRO---- A Chinese Leader in Preclinical & Clinical Service Is Ready To Run

On 27 July 2007, the Company and a Swiss financial corporation, entered into the Note Purchase Agreement in respect of the issue of the Convertible Notes in the principal amount of CHF 15 million (approximately HK$ 97.2 million) due 2012....   more»

Wuxi Pharma Tech »19/08/2007 [Company watch]
China\'s WuXi PharmaTech adds 3 senior level positions to management

China\'s WuXi PharmaTech, a New York Stock Exchange-listed provider of pharmaceutical research and development outsourcing services, said it has added three senior level positions to its management, namely executive vice president of operations, vice president of toxicology and vice president of finance....   more»

3SBIO (Shenyang Sunshine) »15/08/2007 [Company watch]
3SBio Hits Q2 Targets, Reports 50% Increase in Revenue

3SBio (SSRX), the Shenyang biotech that made its U.S. IPO in February, released its second quarter financial report, showing the company greatly increased both revenues and earnings....   more»

Novartis »25/08/2007 [Company watch]
Novartis to move Indian R&D operations to China

Swiss pharmaceutical giant Novartis AG will move hundreds of millions of dollars in planned investments from India to China over the next few years in response to an Indian court ruling that weakens intellectual property rights on new medicines, according to a report on the Financial Times\' Web site....   more»

Bayer »25/08/2007 [Company watch]
merger of the healthcare units of Bayer and Schering nears completion.

Bayer Schering Pharmaceuticals China expects to maintain growth of over 30 percent in the market, as the merger of the healthcare units of Bayer and Schering nears completion....   more»

Hutchison China MediTech Limited(“Chi-Med”) »20/08/2007 [Company watch]
Hutchison China Medipharma agrees collaboration deal with Eli Lilly

Hutchison China Meditech, the China-based pharmaceutical company, said its unit Hutchison MediPharma has agreed a research collaboration with US pharmaceutical company Eli Lilly (NYSE:LLY) to co-develop oncology and anti-inflammatory medicines. Hutchison said it will receive milestone payments of 20-29 mln usd, depending on the clinical candidate, along with an upfront fee, annual research and development support costs and also potential royalties. Under the terms of the agreement, Hutchison will take responsibility for initial research and development, while Eli Lilly will offer technological advice and clinical trial expertise as the project advances. The research will be carried out in China to 'expedite the drug discovery process and reduce overall costs', Hutchison said....   more»

Beijing Med-Pharm »24/08/2007 [Company watch]
Beijing Med-Pharm Hopes To Grow Quickly Through Acquisitions

Beijing Med-Pharm (BJGP) raised $30.6 million (after fees) by placing 3.5 million units, each one consisting of one share and two-tenths of a warrant, at a price of $9.40. Beijing Med-Pharm closed the session Tuesday at $9.29, a loss of 24 cents on the session...   more»

Covance »30/08/2007 [Company watch]
Covance Advances on its Shanghai Lab

Interestingly, Covance said its increased presence in China was due to the higher level of pharmaceutical activity there. Usually, companies invest in China because of some combination of low costs or interest in the country’s growing market for drugs. Because China is expected to be the fifth largest market in the world by 2010 – just three years away – Covance felt the need to be a part of this vital area of pharmaceutical enterprise, to be close to the action. Covance is a $4.5 billion contract research organization with revenues of $1.5 billion annually. During the last week, we noted that big pharma was choosing to build new facilities in China rather than India (see story). Then Novartis (NVS), which just last year announced its intention to make major investments in both countries, reneged on its commitment to India (see story). The cause underlying both stories was poor patent protection in India. For Novartis, the decision was made after the company lost a patent infringement suit against a generic version of leukemia drug Gleevec. Also in the news last week, Beijing Med-Pharm (BJGP) raised $31 million that will allow the company to continue its acquisitive ways (see story), China Shenghuo (KUN) reported much improved Q2 results (see story), Optimer Pharma (OPTR) entered talks with C&O Pharma (of Taiwan, Hong Kong and China) to discuss future collaborations (see story), and China decided to allow its citizens the right to invest in Hong Kong-listed stocks (see story). The change may have the effect of making Hong Kong a more-preferred exchange for biomedical enterprises that are planning their IPOs....   more»

C&O Pharmaceutical Technology (Holdings) Limit »27/08/2007 [Company watch]
Optimer Pharma to Talk Collaboration with C&O On Cross-Licensing Products

Optimer Pharmaceuticals (OPTR) of San Diego signed a non-binding Memorandum of Understanding with C&O Pharmaceutical Technology (Singapore: COPT) to explore potential areas in which the two companies can collaborate. C&O trades on the Singapore exchange; its headquarters are in Hong Kong, and its operations are in mainland China, in the city of Nanjing....   more»

Lotus Pharmaceuticals »21/08/2007 [Company watch]
Lotus Pharmaceuticals, Reports $21 Million in Revenues and $4.1 Million in Net Profits in Quarterly Filing

Lotus Pharmaceuticals, Inc. released its second quarter results, with revenues topping $21 million, net profits of $4.1 million, and net assets of $17 million. r. Adam Wasserman, Lotus Chief Financial Officer, reported: ``Total revenues for the six months ended June 30, 2007 were $21,095,000 as compared to total revenues of $16,047,000 for the six months ended June 30, 2006, an increase of $5,048,000 or approximately 31.5%. Lotus' working capital position increased $4,783,000 to $13,429,000 at June 30, 2007 from $8,646,000 at December 31, 2006.'' Dr. Shaohua Tan, Genesis Director in Beijing, observed: ``Lotus seems to go from strength-to-strength. Just six weeks ago, Gold Horse International joined Lotus as a graduate from our private-to-public program. We are hopeful that a third Chinese partner company, prominent in environmental technologies, will join these alumni as a new U.S. public company before the end of Genesis' current fiscal year.''...   more»

AstraZeneca »05/09/2007 [Company watch]
AstraZeneca ups research capabilities in China

Singapore, September 5, 2007: China plays an increasingly important role as an emerging market in AstraZeneca’s global strategy. In line with this strategy, AstraZeneca entered into a strategic partnership with Peking University 3rd Hospital to open its first Clinical Pharmacology Unit (CPU) in China. The unit aims to enhance local clinical research capabilities and speed up access to new medicines to benefit Chinese patients....   more»

Wuxi Pharma Tech »04/09/2007 [Company watch]
WuXi PharmaTech Co., Ltd. Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007

SHANGHAI, China, Sept. 4 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi PharmaTech" or ''the Company''), the leading China- based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release unaudited financial results for the second quarter ended June 30, 2007 before the US market opens on Thursday, September 6, 2007.(...   more»

Wuxi Pharma Tech »24/08/2007 [Company watch]
WuXi PharmaTech Co., Ltd. CEO Appointed to CrossFire Beilstein Database Advisory Board

SHANGHAI, China, Aug. 24 /Xinhua-PRNewswire/ -- WuXi PharmaTech , China's premier provider of pharmaceutical R&D outsourcing services announced today Dr. Ge Li, the Company's Chairman and Chief Executive Officer, is appointed to a newly established advisory board of Elsevier Information Systems GmbH....   more»

Sanofi-Aventis »15/09/2007 [Company watch]
Sanofi taps into Chinese cancer stem-cell know-how

Sanofi-Aventis has signed a research collaboration agreement with a Chinese institute in the cancer stem-cell field, becoming the latest big drugmaker to tap into China's growing life science skills...   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.